Compare Infosys Limited (INFY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs TG Therapeutics Inc — how do they compare? Infosys Limited trades at $10.74 (market cap $41.74B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Infosys Limited is far larger — about 5.1× TG Therapeutics Inc's market cap, and Infosys Limited pays a 4.89% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and TG Therapeutics Inc for 16 Days on average.
| INFY | TGTX | |
|---|---|---|
Market Cap | $41.74B | $8.16B |
Volume | 31,354,285 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $20.22 | $59.06 |
52-Week Low | $10.49 | $26.94 |
Typical Hold Time | 27 Days | 16 Days |
Enterprise Value | $39.48B | $8.37B |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.73, up 1.71% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025, with a net income margin of 16.37% and a P/E ratio of 13.21. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. News highlights strategic AI collaborations, such as with Columbia University and ABN Amro, aiming to drive innovation.
The outlook is cautious due to bearish technicals and a slight decline in 2026 cash flow projections. Analyst consensus is a 'Hold' with a $11.48 price target, suggesting limited upside. Risks include competitive pressures in IT services and macroeconomic headwinds affecting Western IT spending. The stock's current valuation appears reasonable, but growth catalysts from AI initiatives need to materialize to support a bullish case.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
